Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Form, physiology, and fire response explain key dimensions of litter flammability in fire-adapted longleaf pine savanna.

The New phytologist·2025
Same author

Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer.

Cell reports·2025
Same author

Simultaneous radical cystectomy and nephroureterectomy: A case series.

Surgery in practice and science·2025
Same author

Corynebacterium bovis Growth in Tissue Culture Conditions and Media.

Journal of the American Association for Laboratory Animal Science : JAALAS·2024
Same author

Pubertal exposure to dietary advanced glycation end products disrupts ductal morphogenesis and induces atypical hyperplasia in the mammary gland.

Breast cancer research : BCR·2023
Same author

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.

Cancer genetics·2023
Same journal

Navigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assay.

Expert review of molecular diagnostics·2026
Same journal

Extracellular vesicles as diagnostic and prognostic biomarkers in non-small cell lung cancer.

Expert review of molecular diagnostics·2026
Same journal

Explainable epigenetic aging clocks: an overview of existing AI models and approaches.

Expert review of molecular diagnostics·2026
Same journal

Neuro-axonal injury biomarker serum neurofilament light chain is associated with osteoarthritis: a dual-cohort study from NHANES and UK Biobank.

Expert review of molecular diagnostics·2026
Same journal

Diagnostics and novel laboratory approaches to combat <i>Neisseria gonorrhoeae</i> antimicrobial resistance.

Expert review of molecular diagnostics·2026
Same journal

Fluid biomarkers in cerebral amyloid angiopathy: current limitations and future directions.

Expert review of molecular diagnostics·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
08:23

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

Laboratory methods for KRAS mutation analysis.

Steven M Anderson1

  • 1Laboratory Corporation of America®, 1904 Alexander Drive, Research Triangle Park, NC 27709, USA. sanderson@labcorp.com

Expert Review of Molecular Diagnostics
|July 13, 2011
PubMed
Summary
This summary is machine-generated.

Determining KRAS mutation status is crucial for managing colorectal and lung cancers. Accurate molecular testing guides therapy choices by predicting response to targeted treatments.

More Related Videos

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 31, 2026

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
08:23

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • KRAS mutational status is vital for patient management in colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC).
  • Specific KRAS mutations (codons 12, 13) predict poor response to anti-EGFR therapies in CRC and resistance to TKIs in NSCLC.

Purpose of the Study:

  • To summarize the performance characteristics of various molecular testing methods for KRAS mutations.
  • To highlight the importance of pathologist involvement in sample assessment prior to molecular analysis.
  • To provide information for selecting appropriate therapeutic strategies based on KRAS mutational status.

Main Methods:

  • Review of various laboratory methods for assessing KRAS mutation status, including allele-specific PCR, real-time PCR with melt-curve analysis, and nucleic acid sequencing.
  • Emphasis on analytical performance required to address tumor heterogeneity.
  • Integration of pathological assessment with molecular testing.

Main Results:

  • Multiple molecular methods demonstrate sufficient analytical performance for detecting KRAS mutations.
  • These methods can effectively address tumor heterogeneity.
  • Pathological evaluation is essential for accurate molecular analysis.

Conclusions:

  • KRAS mutation testing is a critical component of personalized medicine in CRC and NSCLC.
  • Accurate and reliable molecular testing methods are available.
  • Informed therapeutic decisions depend on integrating molecular findings with clinical and pathological data.